Milk Science Research Institute, Megmilk Snow Brand Company Limited, 1-1-2 Minamidai, Kawagoe, Saitama 350-1165, Japan.
Br J Nutr. 2013 Nov 14;110(9):1696-703. doi: 10.1017/S0007114513001037. Epub 2013 Apr 25.
Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 % (95 % CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 % (95 % CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.
摄入含有益生菌 Lactobacillus gasseri SBT2055（LG2055）的发酵乳（FM），此前在一项使用含有 10(8) 菌落形成单位（cfu）LG2055/g FM 的随机对照试验（RCT）中显示出腹部肥胖减少。然而，在较低浓度下，即推荐的最低或中间益生菌水平（分别为 10(6) 或 10(7) cfu/g）是否观察到效果，仍有待检验。一项多中心、双盲、平行组 RCT 使用 210 名具有较大内脏脂肪面积（80·2-187·8 cm(2)）的健康日本成年人进行。他们在基线特征上平衡，并随机分配到接受含有 10(7)、10(6) 或 0（对照）cfu LG2055/g FM 的 FM 的三组，并要求他们每天摄入 200 g FM，持续 12 周。通过计算机断层扫描确定的腹部内脏脂肪面积在第 12 周时与基线相比平均变化 -8·5%（95%CI-11·9，-5·1；P<0·01）在 10(7)剂量组，在 10(6)剂量组中变化-8·2%（95%CI-10·8，-5·7；P<0·01）。在两组中，其他指标，包括 BMI、腰围和臀围以及体脂肪量，在第 12 周时也从基线显著下降；有趣的是，停止服用 FM 4 周会减弱这些效果。在对照组中，这些参数均未从基线显著下降。这些发现表明，LG2055 的摄入量低至 10(8) cfu/d 时，对腹部肥胖有显著的降低作用，并表明可能需要持续摄入才能维持效果。
